Miriam Koopman.

Disease control was observed in 94.0 percent of the individuals in the CB group and 94.6 percent of those in the CBC group . Subgroup Analyses The mutation status of the KRAS gene was evaluated in 528 tumors . Eight samples were excluded because of discordance in the total results of the two test methods. An activating KRAS mutation was found in 206 tumors : 108 from individuals in the CB group and 98 from sufferers in the CBC group.1 vs. 10.5 months, P=0.). In comparison with sufferers with mutated-KRAS tumors in the CB group, cetuximab-treated patients with mutated-KRAS tumors had shorter progression-free survival and overall survival .9 percent vs.Other research has found weight-loss surgery can help people reverse their type 2 diabetes, a condition characterized by abnormal blood sugar levels. This reduces the need for medicine and overall health care, the experts stated. And in this study, health-care savings were more apparent in people with more recent diabetes diagnoses. ‘What they say is, we should use functional markers to determine who gets bariatric surgery, and BMI is not the best one to use,’ stated Dr. Mitchell Roslin, chief of obesity surgery at Lenox Hill Medical center in NEW YORK. ‘I would trust that declaration,’ said Roslin, who was simply not involved in the study.